2-113062899-T-C
Position:
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BA1
The NM_012275.3(IL36RN):c.*222T>C variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.648 in 588,930 control chromosomes in the GnomAD database, including 125,218 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.65 ( 32678 hom., cov: 32)
Exomes 𝑓: 0.65 ( 92540 hom. )
Consequence
IL36RN
NM_012275.3 3_prime_UTR
NM_012275.3 3_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: -2.79
Genes affected
IL36RN (HGNC:15561): (interleukin 36 receptor antagonist) The protein encoded by this gene is a member of the interleukin 1 cytokine family. This cytokine was shown to specifically inhibit the activation of NF-kappaB induced by interleukin 1 family, member 6 (IL1F6). This gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2. Two alternatively spliced transcript variants encoding the same protein have been reported. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -13 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.98).
BP6
Variant 2-113062899-T-C is Benign according to our data. Variant chr2-113062899-T-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 330783.We mark this variant Likely_benign, oryginal submissions are: {Benign=2, Uncertain_significance=1}.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.781 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
IL36RN | NM_012275.3 | c.*222T>C | 3_prime_UTR_variant | 5/5 | ENST00000393200.7 | NP_036407.1 | ||
IL36RN | NM_173170.1 | c.*222T>C | 3_prime_UTR_variant | 5/5 | NP_775262.1 | |||
IL36RN | XM_047443918.1 | c.*222T>C | 3_prime_UTR_variant | 6/6 | XP_047299874.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
IL36RN | ENST00000393200.7 | c.*222T>C | 3_prime_UTR_variant | 5/5 | 1 | NM_012275.3 | ENSP00000376896 | P1 | ||
IL36RN | ENST00000346807.7 | c.*222T>C | 3_prime_UTR_variant | 5/5 | 1 | ENSP00000259212 | P1 | |||
IL36RN | ENST00000514072.1 | c.*49+173T>C | intron_variant | 3 | ENSP00000475308 |
Frequencies
GnomAD3 genomes AF: 0.652 AC: 99091AN: 151924Hom.: 32625 Cov.: 32
GnomAD3 genomes
AF:
AC:
99091
AN:
151924
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.646 AC: 282209AN: 436888Hom.: 92540 Cov.: 3 AF XY: 0.655 AC XY: 151507AN XY: 231354
GnomAD4 exome
AF:
AC:
282209
AN:
436888
Hom.:
Cov.:
3
AF XY:
AC XY:
151507
AN XY:
231354
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.652 AC: 99200AN: 152042Hom.: 32678 Cov.: 32 AF XY: 0.656 AC XY: 48748AN XY: 74350
GnomAD4 genome
AF:
AC:
99200
AN:
152042
Hom.:
Cov.:
32
AF XY:
AC XY:
48748
AN XY:
74350
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2743
AN:
3478
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:2
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Acrodermatitis continua suppurativa of Hallopeau Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Clinical Genomics, Uppaluri K&H Personalized Medicine Clinic | - | Patients with Generalized pustular Psoriasis, with certain mutations, respond very well to IL-1 antagonists like Anakinra, as IL36RN mutations upregulate IL-1. IL36RN gene encodes IL-36 receptor antagonist (IL-36Ra), which is required for subsequent activation of intracellular NF-κB and mitogen-activated protein kinase pathways. However, the role of rs2515401 is yet to be ascertained. - |
not provided Benign:1
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Generalized pustular psoriasis Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at